No Data
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8
Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price
Acumen Pharmaceuticals Bets Big on Alzheimer's Trials
Acumen Pharmaceuticals | 10-Q: Quarterly report
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q1 2026 Earnings Conference
106670891 : target price?![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)